Company / Current Liabilities
Fulcrum Therapeutics, Inc. Current Liabilities History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$13.0M
FY2025
5-year range
$11.0M / $19.2M
FY2021-FY2025
Trend
+18.1%
vs FY2024
Sector context
#201 of 213
Health Care
What the data says
Among 213 Health Care companies, Fulcrum Therapeutics, Inc. is in the top 6% for current liabilities. Current Liabilities returned to growth in FY2025 after 4 years of decline, reaching $13M.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -13.4%.
Improved from $14M to $13M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -7.9%
- 5-Year CAGR
- -13.4%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 213This company $13.0M Sector average $1.6B
▼
-99.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -13.4%, indicating a declining trend.
- In FY2025, current liabilities increased 18.1% year-over-year.
- Ranks #201 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.0M | +18.1% |
| FY2024 | $11.0M | -19.2% |
| FY2023 | $13.7M | -18.2% |
| FY2022 | $16.7M | -12.9% |
| FY2021 | $19.2M | -28.2% |
| FY2020 | $26.7M | +120.1% |
| FY2019 | $12.1M | +187.1% |
| FY2018 | $4.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026